Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Prostaglandin E1 (Alprostadil) Infusion
Treatment for Congenital heart anomalies
Typical Dosage: 0.05-0.1 mcg/kg/min continuous IV infusion
Effectiveness
98%
Safety Score
40%
Clinical Trials
1
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
0.05-0.1 mcg/kg/min continuous IV infusion
Time to Effect
Minutes to hours
Treatment Duration
Hours to days (until surgical/catheter intervention)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Confidence Score
99%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$10,000
Side Effect Mgmt:$1,000
Total Annual:$16,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$16,326.53
Prostaglandin E1 (Alprostadil) Infusion Outcomes
for Congenital heart anomalies
Efficacy Outcomes
Overall Effectiveness
+98%
Response Rate
+98%
Common Side Effects
Apnea
+10%
Fever
+10%
Hypotension
+5%
Flushing
+5%
Bradycardia
+2%
Seizures
+1%
Edema
+5%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov